Antidepressant discontinuation syndrome

Primary Psychiatry

Volumn 13, Issue 10, 2006, Pages 23-24

  Robinson, Donald S ^a  

^a Worldwide Drug Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; CENTRAL DEPRESSANT AGENT; FLUOXETINE; HYPNOTIC SEDATIVE AGENT; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN; OPIATE; PAROXETINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ANTIDEPRESSANT DISCONTINUATION SYNDROME; ANXIETY; CHOLINERGIC ACTIVITY; CLINICAL TRIAL; CONCENTRATION LOSS; DEPRESSION; DIAPHORESIS; DIZZINESS; DRUG DEPENDENCE; FATIGUE; GASTROINTESTINAL SYMPTOM; HABITUATION; HEADACHE; HUMAN; INSOMNIA; IRRITABILITY; MENTAL INSTABILITY; NAUSEA; PANIC; RESTLESSNESS; SEIZURE; SHORT SURVEY; SIDE EFFECT; SLEEP DISORDER; TACHYCARDIA; TREATMENT WITHDRAWAL; VOMITING; WITHDRAWAL SYNDROME;

EID: 33750018040     PISSN: 10826319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (18)

1. Andersen H, Kristiansen ES, Tofranil-treatment of endogenous depressions. Acta Psychiatr Scand. 1959;34:387-397.
2. Tyrer P. Clinical effects of abrupt withdrawal from tri-cyclic antidepressants and monoamine oxidase inhibitors after long-term treatment. J Affect Disord. 1984;6(1):1-7.
3. Robinson DS. Benzodiazepines: clinical use and abuse. Primary Psychiatry. 2004;11(5):25-27.
4. Rosenbaum JF, Zajecka J. Clinical management of antidepressant discontinuation. J Clin Psychiatry. 1997;58(suppl 7):37-40.
5. Coupland NJ, Bell CJ, Potokar JP. Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol. 1996;16(5):356-362.
6. Shelton RC. The nature of the discontinuation syndrome associated with antidepressant drugs. J Clin Psychiatry. 2006;67(suppl 4):3-7.
7. Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry. 1998;44(2):77-87.
8. Mallya G, White K, Gunderson C. Is there a serotonergic withdrawal syndrome? Biol Psychiatry. 1993;33(11-12):851-852.
9. Oehrberg S, Christiansen PE, Behnke K, et al. Paroxetine in the treatment of panic disorder: a randomized, double-blind, placebo-controlled study. Br J Psychiatry. 1995;167(3):374-379.
10. Fava M, Mulroy R, Alpert J, Nierenberg AA, Rosenbaum JF. Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine. Am J Psychiatry. 1997;154(12):1760-1762.
11. Michelson D, Fava M, Amsterdam J, et al. Interruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebo-controlled trial. Br J Psychiatry. 2000;176:363-368.
12. Hindmarch I, Kimber S, Cockle SM. Abrupt and brief discontinuation of antidepressant treatment: effects on cognitive function and psychomotor performance. Int Clin Psychopharmacol. 2000;15(6):305-318.
13. Judge R, Parry MG, Quail D, Jacobson JG. Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment. Int Clin Psychopharmacol. 2002;17(5):217-225.
14. Blier P, Tremblay P. Physiologic mechanism underlying the antidepressant discontinuation syndrome. J Clin Psychiatry. 2006;67(suppl 4):8-13.
15. Bergeron R, Blier P. Cisapride for the treatment of nausea produced by selective serotonin reuptake inhibitors. Am J Psychiatry. 1994;151(7):1084-1086.
16. Russell JL. Relatively low doses of cisapride in the treatment of nausea in patients treated with venlafaxine for treatment-refractory depression. J Clin Psychiatry. 1996;16(1):35-37.
17. Szabo ST, de Montigny C, Blier P. Modulation of noradrenergic neuronal firing by selective serotonin reuptake blockers. Br J Pharmacol. 1999;126(3):568-571.
18. Szabo ST, Blier P. Functional and pharmacological characterization of the modulatory role of serotonin on the firing activity of locus coeruleus norepinephrine neurons. Brain Res. 2001;922(1):9-20.